This mirrors results seen in the ACRIN 6657 trial that highlighted the importance of enhancing tumour volume, measured at cycle one, to recurrence-free survival.19 At cycle one of our study, 12 of the 35 tumours were 9 cm3 or larger (7 of these tumours were luminal B, 4 were triple negative and 1 was HER2 enriched). The gene discussed is ERBB2; the disease is neoplasm.